SUNMO: A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy And Safety Of Mosunetuzumab In Combination With Polatuzumab Vedotin In Comparison With Rituximab In Combination With Gemcitabine Plus Oxaliplatin In Participants With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
